NDAINTRAVENOUSSOLUTION
Approved
Aug 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
EPINEPHRINE (epinephrine) by Medica Corp is adrenergic alpha-agonists [moa]. First approved in 2022.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPINEPHRINE is a generic alpha-adrenergic agonist administered intravenously as a solution. It functions as a sympathomimetic agent that stimulates alpha-adrenergic receptors to produce vasconstriction and hemodynamic support. This product is used across acute care settings, particularly in emergency and critical care environments.
Peak
Peak lifecycle stage indicates mature market with established sales infrastructure; competitive pressure at 30% suggests moderate market saturation requiring efficient market management.
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients
Started Sep 2026
44 enrolled
EpinephrineHypersensitivity, ImmediateAnaphylaxis
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Started May 2026
446 enrolled
Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Started Sep 2025
30 enrolled
Distributive ShockHemodynamic AssessmentCritical Illness
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Started May 2025
238 enrolled
Hypotension During Surgery
Worked on EPINEPHRINE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.